


## Primary care rebate schemes

Primary care rebate schemes (PCRS) are contractual arrangements offered by pharmaceutical companies, or third-party companies, which offer retrospective financial rebates to the ICB on GP prescribing expenditure for particular branded medicine(s). The availability of a scheme **does not** influence the inclusion of specific medicines in care pathways or formularies. Healthcare professionals will continue to base their prescribing decisions on individual assessments of their patients' clinical circumstances. The decision to initiate treatment or change a patient's treatment regime should always be based on up-to-date best clinical evidence or guidance, for example, from the National Institute for Health and Clinical Excellence ('NICE'), or other approved authoritative sources.

NCL ICB policy governing primary care rebate schemes can be accessed [here](#).



North Central London ICB has signed up for the following primary care rebate schemes:

Rebate (Brand)	Generic name (if applicable)	Therapeutic area	Start date	End date	Company
Clenil® Modulite® Inhaler	Beclometasone dipropionate	Respiratory	01 April 2024	31 March 2026	Chiesi Limited
FreeStyle® Libre® 2 Plus	N/A	Endocrinology	01 July 2025	30 June 2026	Abbott Laboratories Limited
Fostair® NEXThaler®	Beclometasone dipropionate with formoterol fumarate dihydrate	Respiratory	01 October 2023	31 March 2026	Chiesi Limited
Fostair® pMDI	Beclometasone dipropionate with formoterol fumarate dihydrate	Respiratory	01 April 2024	31 March 2026	Chiesi Limited
Prostap®	Leuprorelin	Endocrinology / Oncology	*	*	Takeda UK Limited
Slenyto®	Melatonin	Neurology	01 July 2023	30 June 2026	Flynn Pharma Ltd
Monopost®	Latanoprost	Ophthalmology	01 August 2025	31 July 2027	Théa Pharma Limited

\*This is classified as "supplier confidential information".



Embrace  
Diversity



Collaborative



Support



Deliver



Efficient



Transparent



Accountable